0000000001156983

AUTHOR

An Sofie Schelpe

0000-0002-3059-364x

showing 1 related works from this author

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

2020

Recently, we showed that ADAMTS13 circulates in an open conformation during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP). Although the cause of this conformational change remains elusive, ADAMTS13 is primarily closed in iTTP patients in remission with ADAMTS13 activity >50% and undetectable anti-ADAMTS13 autoantibodies, as well as after rituximab treatment, suggesting a role for anti-ADAMTS13 autoantibodies. Therefore, immunoglobulin G from 18 acute iTTP patients was purified and added to closed ADAMTS13 in healthy donor plasma. This resulted in open ADAMTS13 in 14 of 18 (78%) samples, proving that anti-ADAMTS13 autoantibodies can induce an open ADAMTS13 con…

Male0301 basic medicine[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematologymedicine.medical_specialtySettore MED/09 - Medicina InternaProtein ConformationImmunologyThrombotic thrombocytopenic purpuraADAMTS13 ProteinBiochemistryImmunoglobulin G03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinehemic and lymphatic diseasesmedicineHumansAutoantibodiesSubclinical infectionPurpura Thrombocytopenic IdiopathicHematology[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologybusiness.industryAutoantibody[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologyMiddle Agedmedicine.diseaseADAMTS133. Good health030104 developmental biologyImmunologybiology.proteinFemaleRituximabRituximabbusinessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies030215 immunologymedicine.drug
researchProduct